Healthcare
Vaxcyte, Inc.(PCVX)
Live Price
Offline$51.61
+0.33% today
1Y Change
+55.45%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $8.19B
- Revenue Growth
- 0.0%
- EPS Growth
- -48.2%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vaxcyte, Inc. (PCVX) is a Healthcare stock with a market cap of $8.19B and listed on NASDAQ. The stock last traded around $51.61 and up 55.5% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -48.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -48.2%, free cash flow -40.9% with operating margin 0.0% and ROIC -32.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PCVX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -48.2%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -9.8% | -5.0% | -14.6% |
2026 Feb 24, 2026 | -17.7% | +2.8% | -2.5% | -10.9% |
2025 Nov 4, 2025 | -22.8% | -2.5% | +10.4% | +15.4% |
Benchmark Edge
PCVX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
PCVX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
PCVX Max Drawdown
-27.95%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PCVX and SPY.
Company Overview
Vaxcyte, Inc.
NASDAQ Global Select
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
- Leadership
- Grant E. Pickering
- IPO Date
- Jun 12, 2020
- Employees
- 414
- Street Address
- 825 Industrial Road
- Mailing
- San Carlos, CA, 94070
- Region
- San Carlos, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 837 0111
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 2.9
Growth
- Revenue
- 0.0%
- EPS
- -48.2%
- Free Cash Flow
- -40.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -25.9%
- ROIC
- -32.5%
Balance Sheet
- Debt/Equity
- 0.09
- Current Ratio
- 7.91
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.